SCHEMBL4770628

SCHEMBL4770628

CCN1CCN(c2nc(-c3ccc(CCCOC)nc3)cc3ccccc23)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
PKN2 Q16513 1/20 0.41
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SYK P43405 1/20 0.40
USP2 O75604 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
PDE5A O76074 1/20 0.38
KCNH2 Q12809 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14102953 0.97 ROCK2 (0.40) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
Oxalic Acid SCHEMBL4775546 0.96 KDM4E (0.40) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4773568 0.92 MYC (0.43) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4765454 0.91 PDE5A (0.44) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4772530 0.90 ROCK2 (0.43) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4765451 0.90 ROCK2 (0.39) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4774753 0.89 ROCK2 (0.42) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4766765 0.89 ROCK2 (0.42) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
Oxalic Acid SCHEMBL4765786 0.88 MYC (0.42) ROCK2ROCK1PKN2KMT2ASMN1; SMN2
SCHEMBL4766096 0.88 ROCK2 (0.41) ROCK2ROCK1PKN2KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US claimed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP claimed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ROCK2 3313/4885ROCK1 2976/4885PKN2 1204/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ROCK2 1825/4885ROCK1 1087/4885PKN2 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.